Anti-idiotype antibody is an antibody against the antigen binding site (complementarity determining region, CDR region) of another antibody. Tracking antibody drug in biological fluid, such as serum from patients receiving antibody drug, requires the differentiation of the administered antibody drug from naturally-occurring endogenous antibodies. As anti-idiotype (anti-ID) antibody is specific to the unique variable region of the antibody drug, it has become a powerful tool for antibody drug pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity studies.
We has extensive experience in developing highly sensitive and highly specific anti-idiotypic antibodies to support your antibody drug development. A major challenge resides in the anti-idiotype antibody development is the very low percentage of anti-ID antibody among other naturally-occurring endogenous antibodies in antibody drug immunized animals. Therefore, the appropriate immunization, purification and hybridoma screening strategies are critical for successful anti-ID polyclonal and monoclonal antibody development. Using the latest and proprietary technologies to ensure the high specificity and affinity of anti-idiotypic antibody, including special adjuvant and immune mediators, super-sensitive hybridoma screening, and optimal clone selection processes. We have accomplished 100% success rate of anti-ID antibody development for our clients.
Features of Anti-ID Antibodies
1. High specificity and affinity
2. Fast turnaround time
3. Proven track record
4. Optimal clone selection: antigen ligand blocking, epitope binning and antibody pairing
5. Availability of both polyclonal and monoclonal anti-idiotype antibody
6. Readily integrated downstream antibody drug PK/PD and immunogenicity assay development
Anti-idiotype Antibody
|
For Quotations & Order Requests
Write to Us : info@ennovationlifesciences.com, ennovationlifesciences@gmail.com
Call Us : +91-9711347133, +91-11-42760231
